fluoroazomycin arabinoside

used for hypoxia-specific imaging; structure in first source

Also Known As:

(18F)-1-alpha-D-(2-deoxy-2-fluoroarabinofuranosyl)-2-nitroimidazole; (18F)-FAZA; (18F)FAZA; (18F)fluoro-azomycinarabino-furanoside; (18F)fluoroazomycinarabinoside; 18F-FAZA; 18F-fluoroazomycin arabinoside; fluoroazomycinarabinoside; 1H-imidazole, 1-(5-deoxy-5-fluoro-alpha-D-arabinofuranosyl)-2-nitro-

Networked: 80 relevant articles (4 outcomes, 24 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Picchio, Maria: 11 articles (07/2021 - 01/2005)
2.	Reischl, Gerald: 10 articles (02/2019 - 01/2005)
3.	Bettinardi, Valentino: 7 articles (07/2021 - 01/2017)
4.	Gianolli, Luigi: 7 articles (07/2021 - 01/2017)
5.	Incerti, Elena: 7 articles (07/2021 - 01/2017)
6.	Mapelli, Paola: 7 articles (07/2021 - 07/2017)
7.	Fallanca, Federico: 6 articles (07/2021 - 01/2017)
8.	Busk, Morten: 6 articles (05/2021 - 03/2008)
9.	Overgaard, Jens: 6 articles (10/2020 - 03/2008)
10.	Kumar, Piyush: 6 articles (01/2018 - 01/2005)

Related Diseases

1.	Hypoxia (Hypoxemia) 01/01/2013 - "Positron emission tomography (PET) using hypoxia tracers such as fluoroazomycin arabinoside (FAZA) may allow identification of patients with hypoxic tumours and the monitoring of the efficacy of hypoxia-targeting treatment. " 08/01/2013 - "This study evaluated tumoural hypoxia using fluoroazomycin arabinoside ((18) F-FAZA) positron emission tomography (PET) scans among patients with locoregionally advanced NSCLC treated with definitive chemoradiation. " 03/15/2010 - "Synthesis, radiofluorination, and hypoxia-selective studies of FRAZ: A configurational and positional analogue of the clinical hypoxia marker, [18F]-FAZA." 10/01/2007 - "This study was performed to evaluate the feasibility of use of (18)F-labelled fluoroazomycin arabinoside ([(18)F]FAZA) for clinical PET imaging of tumour hypoxia. " 12/15/2022 - "Patients underwent screening positron emission tomography (PET) imaging with hypoxia tracer fluoroazomycin arabinoside (FAZA). "
2.	Neoplasms (Cancer) 01/01/2018 - "The comparative analysis in the current study demonstrates that it is feasible to use [18F]FDG PET and [18F]FAZA PET in the same model to analyze their blood PK parameters, and to estimate kinetic parameters for these tracers in tumor. " 01/01/2017 - "A preliminary PET imaging-based biodistribution study of β-[18F]FAZA was performed in A431 tumor-bearing nude mice. " 12/01/2016 - "First PET imaging results with [18F]FAZDR showed advantages over [18F]FAZA regarding higher tumor contrast at earlier time points p.i. Availability of precursor and cold fluoro standard together with high output radiosynthesis will allow for a more detailed quantitative evaluation of [18F]FAZDR, especially with regard to mechanistic studies whether active transport processes are involved, compared to passive diffusion as observed for [18F]FAZA." 12/01/2020 - "PET parameters including [18F]-FDG-SUVmax, [18F]-FAZA-SUVmax, and [18F]-FAZA-tumor-to-muscle [T/M] were obtained. " 10/01/2020 - "Hypoxic tumor volumes can be visualized with 18F-FAZA PET/CT. "
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2017 - "The aim of the present phase I study was to evaluate the biodistribution and dosimetry of 18F-FAZA in non-small cell lung cancer patients. " 11/01/2015 - "This study evaluated the prognostic value of positron emission tomography/computed tomography (PET/CT) using (18) F-fluoroazomycin arabinoside (FAZA) in patients with advanced non-small-cell lung cancer (NSCLC) compared with (18) F-fluorodeoxyglucose (FDG). " 11/01/2015 - "Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer." 11/01/2014 - "Parametric methods for quantification of 18F-FAZA kinetics in non-small cell lung cancer patients." 10/01/2013 - "Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients."
4.	Carcinoma (Carcinomatosis) 11/25/2011 - "Aim of our study was to compare [18F]FAZA uptake in mice with subcutaneous exogenous CT26 colon carcinomas and endogenous polyoma middle-T (PyV-mT) mammary carcinomas and to analyze the influence of different breathing protocols in CT26 colon carcinomas as well as the reversibility or irreversibility of [18F]FAZA uptake. " 08/03/2020 - "We investigated the usefulness of diffusion-weighted imaging (DWI) for detecting changes in the structure of hypoxic cells by evaluating the correlation between 18F-fluoroazomycin arabinoside (FAZA) positron emission tomography activity and DWI parameters in head and neck carcinoma. " 12/01/2016 - "[18F]FAZA or [18F]FAZDR was injected in BALB/c mice bearing CT26 colon carcinoma xenografts, PET scans (10min) were performed after 1, 2 and 3h post injection (p.i.). " 08/03/2020 - "Imaging of Hypoxic Tumor: Correlation between Diffusion-weighted MR Imaging and 18F-fluoroazomycin Arabinoside Positron Emission Tomography in Head and Neck Carcinoma." 12/01/2008 - "Here, we compare the oxygenation-dependent retention of fluoroazomycin arabinoside ([(18)F]FAZA), a promising but not well-characterised hypoxia-specific tracer, and fluorodeoxyglucose ([(18)F]FDG) in four carcinoma cell lines. "
5.	Lung Neoplasms (Lung Cancer) 11/01/2014 - "Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies." 07/01/2017 - "Concomitant Lung Cancer and Gastrointestinal Stromal Tumor: First Report of Hypoxia Imaging With 18F-FAZA PET/CT." 04/01/2017 - "In this study, we analysed the spatial stability of two potential DP targets in lung cancer patients undergoing RT: the tumour burden surrogate [18F]fluorodeoxyglucose (FDG) and the hypoxia surrogate [18F]fluoroazomycin arabinoside (FAZA). " 08/14/2021 - "First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer."

Related Drugs and Biologics

1.	fluoroazomycin arabinoside
2.	Nitroimidazoles
3.	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
4.	3- fluoro- 2- (4- ((2- nitro- 1H- imidazol- 1- yl)methyl)- 1H- 1,2,3- triazol- 1- yl)propan- 1- ol
5.	alovudine
6.	Edotreotide (SMT 487)
7.	alanylaspartic acid
8.	fluoromisonidazole
9.	azomycin
10.	pimonidazole

Related Therapies and Procedures

1.	Precision Medicine
2.	Drug Therapy (Chemotherapy)
3.	Therapeutics
4.	Anesthesia
5.	Radiotherapy